141 related articles for article (PubMed ID: 30652550)
1. Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study.
Innominato P; Komarzynski S; Karaboué A; Ulusakarya A; Bouchahda M; Haydar M; Bossevot-Desmaris R; Mocquery M; Plessis V; Lévi F
JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652550
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project.
Innominato PF; Komarzynski S; Mohammad-Djafari A; Arbaud A; Ulusakarya A; Bouchahda M; Haydar M; Bossevot-Desmaris R; Plessis V; Mocquery M; Bouchoucha D; Afshar M; Beau J; Karaboué A; Morère JF; Fursse J; Rovira Simon J; Levi F
J Med Internet Res; 2016 Nov; 18(11):e305. PubMed ID: 27888171
[TBL] [Abstract][Full Text] [Related]
3. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
[TBL] [Abstract][Full Text] [Related]
4. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
Innominato PF; Giacchetti S; Bjarnason GA; Focan C; Garufi C; Coudert B; Iacobelli S; Tampellini M; Durando X; Mormont MC; Waterhouse J; Lévi FA
Int J Cancer; 2012 Dec; 131(11):2684-92. PubMed ID: 22488038
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
6. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Mormont MC; Waterhouse J; Bleuzen P; Giacchetti S; Jami A; Bogdan A; Lellouch J; Misset JL; Touitou Y; Lévi F
Clin Cancer Res; 2000 Aug; 6(8):3038-45. PubMed ID: 10955782
[TBL] [Abstract][Full Text] [Related]
7. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.
Innominato PF; Focan C; Gorlia T; Moreau T; Garufi C; Waterhouse J; Giacchetti S; Coudert B; Iacobelli S; Genet D; Tampellini M; Chollet P; Lentz MA; Mormont MC; Lévi F; Bjarnason GA;
Cancer Res; 2009 Jun; 69(11):4700-7. PubMed ID: 19470769
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
9. Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948).
Bouchahda M; Ulusakarya A; Thirot-Bidault A; Attari A; Bossevot R; Tuligenga R; Hammel P; Adam R; Levi F
BMJ Open; 2023 Jun; 13(6):e069973. PubMed ID: 37286324
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
11. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
12. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
13. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Lévi F; Zidani R; Brienza S; Dogliotti L; Perpoint B; Rotarski M; Letourneau Y; Llory JF; Chollet P; Le Rol A; Focan C
Cancer; 1999 Jun; 85(12):2532-40. PubMed ID: 10375099
[TBL] [Abstract][Full Text] [Related]
14. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
16. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
[TBL] [Abstract][Full Text] [Related]
17. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Innominato PF; Giacchetti S; Moreau T; Bjarnason GA; Smaaland R; Focan C; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Poncet A; Spiegel D; Lévi F;
Cancer; 2013 Jul; 119(14):2564-73. PubMed ID: 23633399
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
[TBL] [Abstract][Full Text] [Related]
19. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Ortiz-Tudela E; Iurisci I; Beau J; Karaboue A; Moreau T; Rol MA; Madrid JA; Lévi F; Innominato PF
Int J Cancer; 2014 Jun; 134(11):2717-25. PubMed ID: 24510611
[TBL] [Abstract][Full Text] [Related]
20. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
Song Y; Li WW; Huang J
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
